Anxiolytic and Sedative Effects of Dehydroeffusol from Juncus effusus in Mice

Abstract

Dehydroeffusol, a phenanthrene isolated from Juncus effusus L., possesses characteristic anxiolytic and sedative properties, as determined by an array of behavioral tests in mice. In the elevated plus-maze test, dehydroeffusol significantly increased the number of entries into the open arms and the time the mice spent in these arms in a dose-dependent manner, with a minimum effective dose of 2.5 mg/kg. Dehydroeffusol also significantly increased the head-dips of mice in the hole-board test in a dose-dependent manner, with a minimum effective dose of 5 mg/kg. Dehydroeffusol reduced mouse locomotion in the open-field test with a minimum effective dose of 5 mg/kg. In the rota-rod test, 1–5 mg/kg dehydroeffusol did not decrease the fall-down time of mice. The above results confirm that dehydroeffusol possesses anxiolytic and sedative properties and does not affect the general movement coordination of mice. This suggests that dehydroeffusol is a novel anxiolytic chemical derived from herbal medicines.

Key words

anxiolytic - sedative - dehydroeffusol - phenanthrene - Juncus effusus - Juncaceae

References

• 1 Pharmacopoeia of the People's Republic of China (PPRC), English edition, Vol. 1. Beijing; Chinese Ministry of Public Health 2005: 168
• 2 Shima K, Toyota M, Asakawa Y. Phenanthrene derivatives from the medullae of Juncus effusus.  Phytochemistry. 1991;  30 3149-3151
• 3 Della Greca M, Fiorentino A, Mangoni L, Molinaro A, Monaco P, Previtera L. 9,10-Dihydrophenanthrene metabolites from Juncus effusus L.  Tetrahedron Lett. 1992;  33 5257-5260
• 4 Della Greca M, Fiorentino A, Molinaro A, Monaco P, Previtera L. A bioactive dihydrodibenzoxepin from Juncus effusus.  Phytochemistry. 1993;  34 1182-1184
• 5 Della Greca M, Fiorentino A, Mangoni L, Molinaro A, Monaco P, Previtera L. Cytotoxic 9, 10-dihydrophenanthrenes from Juncus effusus L.  Tetrahedron. 1993;  49 3425-3432
• 6 Michela Corsaro M, della Greca M, Fiorentino A, Monaco P, Previtera L. Cycloartane glucosides from Juncus effusus.  Phytochemistry. 1994;  37 515-519
• 7 Della Greca M, Fiorentino A, Monaco P, Previtera L, Zarrelli A. Effusides I–V: 9,10-dihydrophenanthrene glucosides from Juncus effusus.  Phytochemistry. 1995;  40 533-535
• 8 Jin D Z, Min Z D, Chiou G C Y, Iinuma M, Tanaka T. Two p-coumaroyl glycerides from Juncus effusus.  Phytochemistry. 1996;  41 545-547
• 9 Hanawa F, Okamoto M, Towers G H N. Antimicrobial DNA-binding photosensitizers from the common rush, Juncus effusus.  Photochem Photobiol. 2002;  76 51-56
• 10 Della Greca M, Isidori M, Lavorgna M, Monaco P, Previtera L, Zarrelli A. Bioactivity of phenanthrenes from Juncus acutus on Selenastrum capricornutum.  J Chem Ecol. 2004;  30 867-879
• 11 Li H X, Deng T Z, Chen Y, Feng H J, Yang G Z. Isolation and identification of phenolic constituents from Juncus effusus.  Yao Xue Xue Bao. 2007;  42 174-178
• 12 Behery F A, Naeem Z E, Maatooq G T, Amer M M, Wen Z H, Sheu J H, Ahmed A F. Phenanthrenoids from Juncus acutus L., new natural lipopolysaccharide-inducible nitric oxide synthase inhibitors.  Chem Pharm Bull (Tokyo). 2007;  55 1264-1266
• 13 Kovács A, Vasas A, Hohmann J. Natural phenanthrenes and their biological activity.  Phytochemistry. 2008;  69 1084-1110
• 14 Calabrese E J. An assessment of anxiolytic drug screening tests: hormetic dose responses predominate.  Crit Rev Toxicol. 2008;  38 489-542
• 15 Kirschbaum K M, Hiemke C, Schmitt U. Rotarod impairment: catalepsy-like screening test for antipsychotic side effects.  Int J Neurosci. 2009;  119 1509-1522
• 16 Shiotsuki H, Yoshimi K, Shimo Y, Funayama M, Takamatsu Y, Ikeda K, Takahashi R, Kitazawa S, Hattori N. A rotarod test for evaluation of motor skill learning.  J Neurosci Methods. 2010;  189 180-185
• 17 Rex A, Morgenstern E, Fink H. Anxiolytic-like effects of kava-kava in the elevated plus maze test – a comparison with diazepam.  Prog Neuropsychopharmacol Biol Psychiatry. 2002;  26 855-860
• 18 Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand J-P, Soubrié P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.  Proc Natl Acad Sci USA. 2002;  99 6370-6375
• 19 Takeda H, Tsuji M, Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice.  Eur J Pharmacol. 1998;  350 21-29
• 20 Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review.  Eur J Pharmacol. 2003;  463 3-33
• 21 Davidson J R. First-line pharmacotherapy approaches for generalized anxiety disorder.  J Clin Psychiatry. 2009;  70 (Suppl. 2) 25-31
• 22 Sramek J J, Zarotsky V, Cutler N R. Generalised anxiety disorder: treatment options.  Drugs. 2002;  62 1635-1648
• 23 Basile A S, Lippa A S, Skolnick P. Anxioselective anxiolytics: can less be more?.  Eur J Pharmacol. 2004;  500 441-451
• 24 Fernandez S P, Mewett K N, Hanrahan J R, Chebib M, Johnston G A R. Flavan-3-ol derivatives are positive modulators of GABA(A) receptors with higher efficacy for the alpha(2) subtype and anxiolytic action in mice.  Neuropharmacology. 2008;  55 900-907